Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151682 | 0.89 | EDNRA (0.88) | EDNRAEDNRB | |
| SCHEMBL12934035 | 0.89 | EDNRA (0.80) | EDNRAEDNRB | |
| SCHEMBL4631503 | 0.88 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL5208967 | 0.88 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL9063334 | 0.88 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL3634612 | 0.88 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6151554 | 0.87 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL8502911 | 0.87 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6778878 | 0.87 | EDNRA (0.80) | EDNRAEDNRB | |
| SCHEMBL6964505 | 0.86 | EDNRA (0.76) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2009002490-A2 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3-{[(3,4 DIMETHYL-5-ISOXAZOLYL)AMINO]SULFONYL}-2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1498418-B1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1533311-B1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1533311-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| US-5804585-A | INHIBIT BINDING OF ENDOTHELIN PEPTIDE TO ENDOTHELIN RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-09-08 | — | — | US | disclosed |
| CN-1184470-A | Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 1998-06-10 | — | — | CN | disclosed |
| EP-0819125-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| WO-1997039000-A1 | THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5591761-A | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-07 | — | — | US | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | AADAC, B3GNT2, AANAT | EDNRA 1571/4885EDNRB 1119/4885 |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | EDNRB, ECE1, EDNRA | EDNRA 3/4885EDNRB 1/4885 |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | EDNRA, EDNRB, TBXA2R | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.